Skip to main content

and
  1. Article

    Open Access

    Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials

    We sought to identify patient subgroups with distinct postprogression overall survival (ppOS) outcomes and investigate the impact of original treatment assignment and initial postprogression treatment (ppRx) o...

    Paolo A. Ascierto, Antoni Ribas, James Larkin in Journal of Translational Medicine (2020)

  2. Article

    Open Access

    FASCE, the benefit of spironolactone for treating acne in women: study protocol for a randomized double-blind trial

    Acne vulgaris has increased in women over the past 10 years; it currently affects 20–30% of women. The physiopathology of adult female acne is distinguished from that of teenagers essentially by two factors: h...

    Alexandra Poinas, Marie Lemoigne, Sarah Le Naour, Jean-Michel Nguyen in Trials (2020)

  3. Article

    Open Access

    CICAFAST: comparison of a biological dressing composed of fetal fibroblasts and keratinocytes on a split-thickness skin graft donor site versus a traditional dressing: a randomized controlled trial

    Wound repair is one of the most complex biological processes of human life. Allogeneic cell-based engineered skin substitutes provide off-the-shelf temporary wound coverage and act as biologically active dress...

    Alexandra Poinas, Pierre Perrot, Judith Lorant, Olivier Nerrière in Trials (2019)

  4. Article

    Open Access

    Efficient treatment of a metastatic melanoma patient with a combination of BRAF and MEK inhibitors based on circulating tumor DNA analysis: a case report

    Fixed tissues are the standard samples used in routine practice for molecular testing. But sometimes tissues are lacking or difficult to obtain. In these cases, circulating tumor DNA released from tumor cells ...

    Gaelle Quéreux, Guillaume Herbreteau, Anne-Chantal Knol in BMC Research Notes (2017)

  5. Article

    Open Access

    Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study

    Serous chorioretinopathy has been associated with MEK inhibitors, including cobimetinib. We describe the clinical features of serous retinopathy observed with cobimetinib in patients with BRAF ...

    Luis de la Cruz-Merino, Lorenza Di Guardo in Journal of Translational Medicine (2017)

  6. Article

    Open Access

    Melanoma and immunotherapy bridge 2015

    MELANOMA BRIDGE 2015

    Vashisht G. Y. Nanda, Weiyi Peng, Patrick Hwu in Journal of Translational Medicine (2016)

  7. Article

    Open Access

    coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)

    Paolo A Ascierto, Grant A. McArthur, Brigitte Dréno in Journal of Translational Medicine (2015)

  8. Article

    Open Access

    A subset of dendritic cells as a major and constitutive source of IL-22BP

    Jérôme Martin, Gaelle Bériou, Michèle Heslan in Journal of Translational Medicine (2011)

  9. Article

    Open Access

    Value of large scale expansion of tumor infiltrating lymphocytes in a compartmentalised gas-permeable bag: interests for adoptive immunotherapy

    Adoptive cell therapy (ACT) has emerged as an effective treatment for patients with metastatic melanoma. However, there are several logistical and safety concerns associated with large-scale ex vivo expansion of ...

    Thomas Zuliani, Julien David, Sylvain Bercegeay in Journal of Translational Medicine (2011)